Bellon Steven F.
Known title: Chief Scientific OfficerCIK: 0001831749
Associated companies
Transaction History
| FHTX | ▼ Sell | Open Market | 20,000 | $190K | 9/9/2024 | View on chart |
| FHTX | ▲ Buy | Option Exercise | 1,858 | $7K | 8/11/2022 | View on chart |
| FHTX | ▲ Buy | Option Exercise | 675 | $493 | 5/25/2022 | View on chart |
| FHTX | ▲ Buy | Option Exercise | 3,717 | $14K | 5/25/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Foghorn and Lilly halt FHD-909 development
Foghorn Therapeutics announced it will not advance the FHD-909 program into the clinical development expansion phase with Lilly. This decision marks a significant setback for the company's pipeline, as it halts progress on a key partnership. The news explains why the stock is trading near its 52-week low, reflecting the impact of this strategic pause on market sentiment.
Foghorn and Lilly halt FHD-909 development. Foghorn Therapeutics announced it will not advance the FHD-909 program into the clinical development expansion phase with Lilly. This decision marks a significant setback for the company's pipeline, as it halts progress on a key partnership. The news explains why the stock is trading near its 52-week low, reflecting the impact of this strategic pause on market sentiment.